Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma

Giorgio Perilongo; Rudolf Maibach; Elisabeth Shafford; Laurence Brugieres; Penelope Brock; Bruce Morland; Beatriz de Camargo; Jozsef Zsiros; Derek Roebuck; Arthur Zimmermann; Daniel Aronson; Margaret Childs; Eva Widing; Veronique Laithier; Jack Plaschkes; Jon Pritchard; Marcello Scopinaro; Gordon MacKinlay; Piotr Czauderna

doi:10.1056/NEJMoa0810613

Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma

Giorgio Perilongo
, Rudolf Maibach
, Elisabeth Shafford
, Laurence Brugieres
, Penelope Brock
, Bruce Morland
, Beatriz de Camargo
, Jozsef Zsiros
, Derek Roebuck
, Arthur Zimmermann
, Daniel Aronson
, Margaret Childs
, Eva Widing
, Veronique Laithier
, Jack Plaschkes
, Jon Pritchard
, Marcello Scopinaro
, Gordon MacKinlay
, Piotr Czauderna

Cancer and Genomic Sciences

Research output: Contribution to journal › Article › peer-review

175 Citations (Scopus)

Abstract

Preoperative cisplatin alone may be as effective as cisplatin plus doxorubicin in standard-risk hepatoblastoma (a tumor involving three or fewer sectors of the liver that is associated with an alpha-fetoprotein level of >100 ng per milliliter).

Original language	English
Pages (from-to)	1662-70
Number of pages	9
Journal	The New England Journal of Medicine
Volume	361
Issue number	17
DOIs	https://doi.org/10.1056/NEJMoa0810613
Publication status	Published - 22 Oct 2009

Bibliographical note

2009 Massachusetts Medical Society

Keywords

Antineoplastic Agents
Antineoplastic Combined Chemotherapy Protocols
Biopsy
Chemotherapy, Adjuvant
Child
Child, Preschool
Cisplatin
Disease Progression
Doxorubicin
Female
Hepatoblastoma
Humans
Infant
Liver Neoplasms
Male
Neoplasm Recurrence, Local
Survival Analysis

Access to Document

10.1056/NEJMoa0810613

Cite this

Perilongo, G., Maibach, R., Shafford, E., Brugieres, L., Brock, P., Morland, B., de Camargo, B., Zsiros, J., Roebuck, D., Zimmermann, A., Aronson, D., Childs, M., Widing, E., Laithier, V., Plaschkes, J., Pritchard, J., Scopinaro, M., MacKinlay, G., & Czauderna, P. (2009). Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma. The New England Journal of Medicine, 361(17), 1662-70. https://doi.org/10.1056/NEJMoa0810613

@article{937dbb1dd729484f8cab6d73251dd0a1,

title = "Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma",

abstract = "Preoperative cisplatin alone may be as effective as cisplatin plus doxorubicin in standard-risk hepatoblastoma (a tumor involving three or fewer sectors of the liver that is associated with an alpha-fetoprotein level of >100 ng per milliliter).",

keywords = "Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Biopsy, Chemotherapy, Adjuvant, Child, Child, Preschool, Cisplatin, Disease Progression, Doxorubicin, Female, Hepatoblastoma, Humans, Infant, Liver Neoplasms, Male, Neoplasm Recurrence, Local, Survival Analysis",

author = "Giorgio Perilongo and Rudolf Maibach and Elisabeth Shafford and Laurence Brugieres and Penelope Brock and Bruce Morland and \{de Camargo\}, Beatriz and Jozsef Zsiros and Derek Roebuck and Arthur Zimmermann and Daniel Aronson and Margaret Childs and Eva Widing and Veronique Laithier and Jack Plaschkes and Jon Pritchard and Marcello Scopinaro and Gordon MacKinlay and Piotr Czauderna",

note = "2009 Massachusetts Medical Society",

year = "2009",

month = oct,

day = "22",

doi = "10.1056/NEJMoa0810613",

language = "English",

volume = "361",

pages = "1662--70",

journal = "The New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachusetts Medical Society",

number = "17",

}

Perilongo, G, Maibach, R, Shafford, E, Brugieres, L, Brock, P, Morland, B, de Camargo, B, Zsiros, J, Roebuck, D, Zimmermann, A, Aronson, D, Childs, M, Widing, E, Laithier, V, Plaschkes, J, Pritchard, J, Scopinaro, M, MacKinlay, G & Czauderna, P 2009, 'Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma', The New England Journal of Medicine, vol. 361, no. 17, pp. 1662-70. https://doi.org/10.1056/NEJMoa0810613

TY - JOUR

T1 - Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma

AU - Perilongo, Giorgio

AU - Maibach, Rudolf

AU - Shafford, Elisabeth

AU - Brugieres, Laurence

AU - Brock, Penelope

AU - Morland, Bruce

AU - de Camargo, Beatriz

AU - Zsiros, Jozsef

AU - Roebuck, Derek

AU - Zimmermann, Arthur

AU - Aronson, Daniel

AU - Childs, Margaret

AU - Widing, Eva

AU - Laithier, Veronique

AU - Plaschkes, Jack

AU - Pritchard, Jon

AU - Scopinaro, Marcello

AU - MacKinlay, Gordon

AU - Czauderna, Piotr

N1 - 2009 Massachusetts Medical Society

PY - 2009/10/22

Y1 - 2009/10/22

N2 - Preoperative cisplatin alone may be as effective as cisplatin plus doxorubicin in standard-risk hepatoblastoma (a tumor involving three or fewer sectors of the liver that is associated with an alpha-fetoprotein level of >100 ng per milliliter).

AB - Preoperative cisplatin alone may be as effective as cisplatin plus doxorubicin in standard-risk hepatoblastoma (a tumor involving three or fewer sectors of the liver that is associated with an alpha-fetoprotein level of >100 ng per milliliter).

KW - Antineoplastic Agents

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Biopsy

KW - Chemotherapy, Adjuvant

KW - Child

KW - Child, Preschool

KW - Cisplatin

KW - Disease Progression

KW - Doxorubicin

KW - Female

KW - Hepatoblastoma

KW - Humans

KW - Infant

KW - Liver Neoplasms

KW - Male

KW - Neoplasm Recurrence, Local

KW - Survival Analysis

U2 - 10.1056/NEJMoa0810613

DO - 10.1056/NEJMoa0810613

M3 - Article

C2 - 19846851

SN - 0028-4793

VL - 361

SP - 1662

EP - 1670

JO - The New England Journal of Medicine

JF - The New England Journal of Medicine

IS - 17

ER -

Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma

Abstract

Bibliographical note

Keywords

Access to Document

Fingerprint

Cite this